Recommended and actual lepirudin doses in patients with renal insufficiency

American Journal of Health-System Pharmacy

Volumn 60, Issue 24, 2003, Pages 2588-2593

  Saxer, Sarah B ^a,b   Smith, Brian S ^b   Gandhi, Pritesh J ^c   Tataronis, Gary R ^c   Krikorian, Susan A ^d  

^a Solid Organ Transplantation   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

^c Department of Clinical Pharmacy ^*

^d MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ANTICOAGULANT AGENT; DRUG DERIVATIVE; HIRUDIN DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FAILURE; PRESCRIPTION; PRIORITY JOURNAL; AGED; CHEMICALLY INDUCED DISORDER; THROMBOCYTOPENIA; UNITED STATES;

AGED; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPARIN; HIRUDINS; HUMANS; KIDNEY FAILURE; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; UNITED STATES;

EID: 1642399160     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.24.2588     Document Type: Article

References (33)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996; 101:502-7.
2. Kelton JG. Heparin-induced thrombocytopenia. Haemostasis. 1986; 16:173-86.
3. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med. 1984; 100:535-40.
4. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb. 1991; 10:1-34.
5. Warkentin TE. Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management. Drug Saf. 1997; 17:325-41.
6. Greinacher A, Janssens U, Berg G et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999; 100:587-93.
7. Greinacher A, Volpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999; 99:73-80.
8. Refludan (lepirudin) package insert. Kansas City, MO: Hoechst Marion Roussel; 1998 Oct.
9. Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of argatroban. J Thromb Thrombolysis. 2001; 12:141-9.
10. Schiele F, Vuillemenot A, Dramarz P et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995; 50:20-5.
11. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998; 79:1-7.
12. Song X, Huhle G, Wang L et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation. 1999; 100:1528-32.
13. Eichler P, Greinacher A. Anti-hirudin antibodies induced by recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT). Ann Hematol 1996; 72(suppl):A4. Abstract.
14. Eichler P, Friesen H, Lubenow N et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000; 96:2373-8.
15. Markwardt F, Nowak G, Sturzebecher J et al. Clinicopharmacological studies with recombinant hirudin. Thromb Res. 1988; 52:393-400.
16. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 1994; 74:1-16.
17. Nowak G, Bucha E, Goock T et al. Pharmacology of r-hirudin in renal impairment. Thromb Res. 1992; 66:707-15.
18. Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother. 1999; 33:236-40.
19. Jick H. Adverse drug effects in relation to renal function. Am J Med. 1977; 62:514-7.
20. Kelly WN. Potential risks and prevention, part 4: reports of significant adverse drug events. Am J Health-Syst Pharm. 2001; 58: 1406-12.
21. Leape LL, Bates DW, Cullen DJ et al. Systems analysis of adverse drug events. JAMA. 1995; 274:35-43.
22. Phillips J, Beam S, Brinker A et al. Retrospective analysis of mortalities associated with medication errors. Am J Health-Syst Pharm. 2001; 58:1835-41.
23. Wittkowsky A, Kondo L. Lepirudin dosing in dialysis-dependent renal failure. Pharmacotherapy. 2000; 20:1123-8.
24. Fisher K-G, Van De Loo A, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int. 1999; 56:546-50.
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
26. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993; 329:673-82.
27. Chesebro JH, Knatterud G, Roberts R et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987; 76:142-54.
28. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. Thromb Haemost. 1994; 72:685-92.
29. Potzsch B, Hund S, Madlener K et al. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res. 1997; 86:373-83.
30. Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost. 1996; 22:197-202.
31. Kornalik F, Blomback B. Prothrombin activation induced by ecarin-a prothrombin converting enzyme from Echis carinatus venom. Thromb Res. 1975; 6:57-63.
32. Morita T, Iwanaga S, Suzuki T. The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venom and characterization of the new active intermediates. J Biochem. 1976; 79:1089-108.
33. Greinacher A, Eichler P, Lubenow N et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000; 96:846-51.